drugset / Trial / NCT00154427

Use of Activated Recombinant Human Factor VII in Cardiac Surgery

NCT00154427

Phase 2 Terminated 172 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Africa, Asia, Europe, South America and the United States of America (USA). The trial is planned to investigate the safety and efficacy of NovoSeven® in the management of post-operative bleeding in patients following cardiac surgery.

Timeline

Start
2004-08
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject eptacog alfa (activated) Protein / enzyme biologic 40 ug/kg
Subject eptacog alfa (activated) Protein / enzyme biologic 80 ug/kg